CD274 and non-small cell lung carcinoma: This paper aims to evaluate the efficacy of pembrolizumab monotherapy in metastatic non-oncogene-addicted NSCLC patients with a PD-L1 TPS ≥ 50% aged 70 and older and compare it to patients younger than 70 based on real-world data collected from academic institutions in Central and Southeastern Europe.